



Aptamer-Based Targeted Conjugates for Diagnostic and Therapeutic Applications

Guest Editors:

Dr. Laura Cerchia

Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), Naples, Italy

Dr. Simona Camorani

Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), Naples, Italy

Deadline for manuscript submissions:

closed (10 November 2021)

Message from the Guest Editors

The mainstay of a therapeutic intervention is to specifically target diseased cells or tissues at high accuracy with low frequency of adverse side effects. One possibility to reach this goal is to use disease-specific ligands as delivery agents to drive therapeutic cargos to the diseased sites while sparing the healthy ones. Oligonucleotide aptamers, analogously to protein antibodies, interact tightly with their targets because of their complex shapes, thus representing a useful class of molecular recognition probes in various diagnostic and therapeutic applications. The quick chemical production, design flexibility, and versatile chemical modification that allow different conjugation chemistries renders aptamers ideal targeting moieties in advanced targeted delivery strategies. Antibody-based targeted therapeutics provide high target specificity and affinity. The present Special Issue will include original research articles and review articles aimed at covering new synthetic methodologies of aptamer conjugates as well as their novel applications.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma